Multimodale Therapie beim lokal fortgeschrittenen Magenkarzinom

Institut 1 Klinik für Strahlentherapie und Radiologische Onkologie, Universitätsklinik Düsseldorf 2 Klinik für Allgemein-, Viszeralund Unfallchirurgie, Kliniken Essen-Süd, Essen 3 Klinik für Allgemein, Viszeralund Kinderchirurgie, Universitätsklinik Düsseldorf 4 Institut für Pathologie, Universitätsklinik Düsseldorf 5 Klinik für Hämatoonkologie, Onkologie und Klinische Immunologie, Universitätsklinik Düsseldorf 6 Klinik für Gastroenterologie, Hepatologie und Infektiologie, Universitätsklinik Düsseldorf 7 Klinik für Visceralund Gefäßchirurgie, Klinikum Region Hannover

[1]  P. Schlag,et al.  Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Langer,et al.  Significance of Histopathological Tumor Regression After Neoadjuvant Chemotherapy in Gastric Adenocarcinomas: A Summary of 480 Cases , 2011, Annals of surgery.

[3]  P. Schlag,et al.  Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Sakurai,et al.  Clinical Results of Proton-Beam Therapy for Locoregionally Advanced Esophageal Cancer , 2010, Strahlentherapie und Onkologie.

[5]  C. Belka,et al.  Long-Term Outcome of Mitomycin C- and 5-FU-Based Primary Radiochemotherapy for Esophageal Cancer , 2010, Strahlentherapie und Onkologie.

[6]  E. Steyerberg,et al.  Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. , 2010 .

[7]  H. Putter,et al.  Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Thieke,et al.  Catch Me if You Can – the Use of Image Guidance in the Radiotherapy of an Unusual Case of Esophageal Cancer , 2009, Strahlentherapie und Onkologie.

[9]  E. Van Cutsem,et al.  Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Willett,et al.  Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Stuschke,et al.  Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Ajani,et al.  Response to Preoperative Therapy in Upper Gastrointestinal Cancers , 2009, Annals of Surgical Oncology.

[13]  L. Collette,et al.  European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. , 2008, European journal of cancer.

[14]  A. Nashimoto,et al.  D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. , 2008, The New England journal of medicine.

[15]  T. Conroy,et al.  Outcome of the nonrandomized patients in the FFCD 9102 trial: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus , 2008 .

[16]  M. Schwaiger,et al.  Early Metabolic Response Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows In vivo Testing of Chemosensitivity in Gastric Cancer: Long-term Results of a Prospective Study , 2008, Clinical Cancer Research.

[17]  H. Deere,et al.  Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy: practical guidelines and current issues. , 2008, American journal of clinical pathology.

[18]  Yasuo Ohashi,et al.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. , 2007, The New England journal of medicine.

[19]  V. Rusch,et al.  Endoscopic ultrasound predicts outcomes for patients with adenocarcinoma of the gastroesophageal junction. , 2007, Journal of the American College of Surgeons.

[20]  Wolfgang A Weber,et al.  PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. , 2007, The Lancet. Oncology.

[21]  A. Boulesteix,et al.  Methylation of Tumor-Related Genes in Neoadjuvant-Treated Gastric Cancer: Relation to Therapy Response and Clinicopathologic and Molecular Features , 2007, Clinical Cancer Research.

[22]  V. Rusch,et al.  Adenocarcinoma of the Gastroesophageal Junction: Influence of Esophageal Resection Margin and Operative Approach on Outcome , 2007, Annals of surgery.

[23]  J. Pignon,et al.  Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial , 2007 .

[24]  H. Höfler,et al.  The thymidylate synthase tandem repeat promoter polymorphism: A predictor for tumor‐related survival in neoadjuvant treated locally advanced gastric cancer , 2006, International journal of cancer.

[25]  M. Schwaiger,et al.  Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Nashimoto,et al.  Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. , 2006, The Lancet. Oncology.

[27]  C. Reed,et al.  Superiority of trimodality therapy to surgery alone in esophageal cancer: Results of CALGB 9781. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Höfler,et al.  The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas , 2006, Cancer.

[29]  Jen-Hao Chen,et al.  Nodal dissection for patients with gastric cancer: a randomised controlled trial. , 2006, The Lancet. Oncology.

[30]  Joon-Oh Park,et al.  An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. , 2005, International journal of radiation oncology, biology, physics.

[31]  M. Schwaiger,et al.  Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  S. Baldus,et al.  Histomorphologic Tumor Regression and Lymph Node Metastases Determine Prognosis Following Neoadjuvant Radiochemotherapy for Esophageal Cancer: Implications for Response Classification , 2005, Annals of surgery.

[33]  A. Venturi,et al.  Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis , 2004, Gut.

[34]  M. Schwaiger,et al.  Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  H. Höfler,et al.  Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  M. Feith,et al.  Neoadjuvant treatment of esophageal cancer: Immunosuppression following combined radiochemotherapy. , 2002, Surgery.

[37]  Aller,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2002, The New England journal of medicine.

[38]  M. Schwaiger,et al.  Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Iannettoni,et al.  Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  C. Earle,et al.  Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. , 1999, European journal of cancer.

[41]  W. Yin,et al.  Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)--report on 370 patients. , 1998, International journal of radiation oncology, biology, physics.

[42]  T. Walsh,et al.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. , 1996, The New England journal of medicine.

[43]  H. Putter,et al.  Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. , 2010, The Lancet. Oncology.

[44]  H. Feußner,et al.  [Staging laparoscopy in oncology]. , 2006, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[45]  H. Katai,et al.  Pancreaticoduodenectomy for advanced gastric cancer , 2004, Gastric Cancer.

[46]  U. Vanhoefer,et al.  Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer , 2004, Journal of Cancer Research and Clinical Oncology.

[47]  B. Glimelius,et al.  Chemotherapy in gastric cancer: a review and updated meta-analysis. , 2002, The European journal of surgery = Acta chirurgica.

[48]  J. Ajani,et al.  Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. , 1999, Annals of surgery.

[49]  J. Siewert,et al.  [Intestinal pouches: gastric reconstruction]. , 1999, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[50]  J. Siewert,et al.  New developments in the treatment of gastric carcinoma. , 1991, Cancer treatment and research.